Inventor · disambiguated record
Jens-Peter Volkmer
Also filed as: VOLKMER JENS-PETER
30 granted patents·14 pending applications·153 citations·filing 2014–2024
96Inventor score
Top patents by PatentIndex Score
44 records- 0198US11518806B2Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibodyUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Dec 6, 2022·6 cites·34 claims
- 0297US11136391B2Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibodyUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Oct 5, 2021·9 cites·17 claims
- 0396US11603404B2Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibodyUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Mar 14, 2023·3 cites·36 claims
- 0496US11141480B2Dosing parameters for CD47 targeting therapies to hematologic malignanciesUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Oct 12, 2021·9 cites·6 claims
- 0596US10781256B2Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodiesUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Sep 22, 2020·14 cites·14 claims
- 0696US10081680B2Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodiesUNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Sep 25, 2018·42 cites·15 claims
- 0796US9623079B2Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancerUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Apr 18, 2017·26 cites·12 claims
- 0894US10611842B2Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapyUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Apr 7, 2020·8 cites·15 claims
- 0994US10301387B2Methods for achieving therapeutically effective doses of anti-CD47 agentsUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted May 28, 2019·11 cites·15 claims
- 1091US10344094B2Treatment of cancer with dual targeting of CD47 and EGFRUNIV LELAND STANFORD JUNIOR·Filed 2016·Granted Jul 9, 2019·6 cites·9 claims
- 1190US10780117B2Macrophages eat cancer cells using their own calreticulin as a guideUNIV LELAND STANFORD JUNIOR·Filed 2016·Granted Sep 22, 2020·5 cites·11 claims
- 1287US10618976B2SIRP-α agonist antibodyUNIV LELAND STANFORD JUNIOR·Filed 2016·Granted Apr 14, 2020·5 cites·7 claims
- 1386US12258403B2Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibodyUNIV LELAND STANFORD JUNIOR·Filed 2023·Granted Mar 25, 2025·0 cites·19 claims
- 1485US12194093B2Dosing parameters for CD47 targeting therapies to hematologic malignanciesUNIV LELAND STANFORD JUNIOR·Filed 2023·Granted Jan 14, 2025·0 cites·6 claims
- 1584US10064925B2Use of anti-CD47 agents to enhance immunizationUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Sep 4, 2018·7 cites·4 claims
- 1683US12318448B2Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cellsUNIV LELAND STANFORD JUNIOR·Filed 2023·Granted Jun 3, 2025·0 cites·9 claims
- 1780US12258399B2Methods for achieving therapeutically effective doses of anti-CD47 agentsUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Mar 25, 2025·0 cites·18 claims
- 1880US11718670B2Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancerUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Aug 8, 2023·0 cites·14 claims
- 1980US2025066473A1Treatment of cancer with combinations of immunoregulatory agentsUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 2079US10961318B2Anti-SIRP-α antibodies and related methodsFORTY SEVEN INC·Filed 2018·Granted Mar 30, 2021·1 cites·33 claims
- 2179US2023406923A1Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancerUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 2277US12274746B2Dosing parameters for CD47 targeting therapies to hematologic malignanciesUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Apr 15, 2025·0 cites·11 claims
- 2377US11891450B2Anti-CD47 agent-based treatment of CD20-positive cancerFORTY SEVEN INC·Filed 2019·Granted Feb 6, 2024·1 cites·20 claims
- 2473US11104731B2Compositions for achieving therapeutically effective doses of anti-CD47 agentsUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Aug 31, 2021·0 cites·2 claims
- 2573US2024218077A1Anti-cd47 agent-based treatment of cd20-positive cancerFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 2672US2024150461A1Anti-cd47 agent-based ovarian cancer therapyFORTY SEVEN INC·Filed 2023·Application pending·0 cites
- 2771US12037402B2Treatment of cancer with dual targeting of CD47 and EGFRUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Jul 16, 2024·0 cites·7 claims
- 2870US11130813B2Treatment of cancer with dual targeting of CD47 and EGFRUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Sep 28, 2021·0 cites·8 claims
- 2968US11766454B2Use of TLR agonist and anti-CD47 agent to enhance phagocytosis of cancer cellsUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Sep 26, 2023·0 cites·10 claims
- 3068US11753480B2Anti-SIRP-alpha antibodies and related methodsFORTY SEVEN INC·Filed 2021·Granted Sep 12, 2023·0 cites·23 claims
- 3166US2021230276A1Treatment of cancer with combinations of immunoregulatory agentsUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3265US11718675B2Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPalpha antibody therapyUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Aug 8, 2023·0 cites·14 claims
- 3365US2023365648A1Sirp-alpha fusion polypeptides with modified fc domainsBITTERROOT BIO INC·Filed 2023·Application pending·0 cites
- 3465US2025257113A1Multivalent sirp-alpha fusion polypeptidesUNIV LELAND STANFORD JUNIOR·Filed 2023·Application pending·0 cites
- 3564US11154600B2Use of anti-CD47 agents to enhance immunizationUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Oct 26, 2021·0 cites·5 claims
- 3662US11802153B2Anti-CD47 agent-based ovarian cancer therapyFORTY SEVEN INC·Filed 2018·Granted Oct 31, 2023·0 cites·17 claims
- 3762US11472878B2Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancerUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Oct 18, 2022·0 cites·10 claims
- 3851US2022185905A1Multispecific agents for treatment of cancerFORTY SEVEN INC·Filed 2020·Application pending·0 cites
- 3950US2017210803A1Treatment of cancer with combinations of immunoregulatory agentsUNIV LELAND STANFORD JUNIOR·Filed 2017·Application pending·0 cites
- 4049US2022119523A1Treatment of cutaneous t cell lymphoma with targeting of cd47 pathwayUNIV LELAND STANFORD JUNIOR·Filed 2020·Application pending·0 cites
- 4149US2020369767A1Regimes for co-administration of immunotherapeutic agents against c-kit and cd47FORTY SEVEN INC·Filed 2020·Application pending·0 cites
- 4247US2022288118A1Depletion regimes for engineered t-cell or nk-cell therapyFORTY SEVEN INC·Filed 2020·Application pending·0 cites
- 4347US2022023348A1Genetically modified hspcs resistant to ablation regimeFORTY SEVEN INC·Filed 2019·Application pending·0 cites
- 4444US2021047416A1Treatment of ovarian cancer with anti-cd47 and anti-pd-l1FORTY SEVEN INC·Filed 2018·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →